Compare Stryker Corporation (SYK) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Symbotic Inc — how do they compare? Stryker Corporation trades at $277.48 (market cap $106.24B), while Symbotic Inc trades at $42.66 (market cap $5.46B). The key difference: Stryker Corporation is far larger — about 19.5× Symbotic Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stryker Corporation for 21 Days and Symbotic Inc for 23 Days on average.
| SYK | SYM | |
|---|---|---|
Market Cap | $106.24B | $5.46B |
Volume | 2,982,001 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $388.35 | $87.30 |
52-Week Low | $269.75 | $38.22 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $117.70B | $3.72B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
SYM trades at $42.56, down 1.73% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $16.94 million in 2025, though revenue grew to $2.25 billion. Analysts maintain a consensus Buy rating with a $60.33 price target, citing a robust $22.5 billion backlog and positioning in warehouse automation.
The outlook hinges on execution of its large backlog and diversification beyond key customer Walmart. Near-term risks include recent earnings misses and high valuation multiples relative to current profitability. The stock offers growth potential if margin expansion and recurring revenue targets are met, but faces volatility from execution risks and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
